Adverse Event Atlas
Comprehensive surveillance of every documented adverse event in medicinal leech therapy — frequencies, mechanisms, management protocols, and primary literature
Last updated: June 18, 2026
Cross-referenced safety protocols
Why a Comprehensive Adverse Event Atlas
Patient safety in hirudotherapy depends on systematic awareness of every documented adverse event — common (Aeromonas infection, post-detachment bleeding, mild allergic reactions) AND rare (anaphylaxis, sepsis, vasovagal syncope, meningitis). The published literature contains scattered case reports and series; institutional surveillance varies. This Atlas consolidates 30+ documented adverse events with frequencies, mechanisms, primary literature, and management protocols.
The Atlas is organized by severity tier (common/uncommon/rare/very rare). Each event includes: frequency estimate with source, mechanism explanation, clinical presentation, evidence-based management, prevention notes, and FDA MAUDE database trends where applicable.
Important: This Atlas is a safety reference for clinicians, not patient-facing communication. Patient-facing safety information is provided in the Patient Guide and Patient FAQs. Some events listed have been documented only as case reports; their inclusion does not imply common occurrence but supports comprehensive clinical awareness.
Frequency Tier Key
Common
≥1% of patients
Uncommon
0.1-1% of patients
Rare
0.01-0.1% of patients
Very Rare
<0.01% of patients; isolated case reports
30 Documented Adverse Events
Aeromonas Wound InfectionCommon (without prophylaxis); Uncommon (with prophylaxis)
Frequency
7-20% without prophylaxis; <5% with proper antibiotic prophylaxis; 0% reported in protocol-driven series (Nguyen 2012, n=39)
Mechanism
Aeromonas veronii (60-90% of leech microbiome) and A. hydrophila are obligate gut symbionts of the leech. Bacterial transfer occurs during leech feeding — bacteria from the leech digestive tract enter the wound at the bite site. Symbiont colonization is established during the leech's first blood meal and cannot be eliminated without killing the leech.
Presentation
Local cellulitis with redness, warmth, pain, induration around bite site, typically appearing 24 hours to 26 days post-treatment. Severe presentations include bacteremia, sepsis, deep tissue infection, and rare cases of necrotizing fasciitis. Late-onset infection up to 26 days is documented; standard surveillance window should be 4 weeks.
Management
Empiric therapy: third-generation cephalosporin (ceftriaxone 2 g IV q24h) plus ciprofloxacin 400 mg IV q12h pending susceptibility. Susceptibility-guided therapy targeting Aeromonas hydrophila typically responsive to fluoroquinolones, TMP-SMX, third-generation cephalosporins, aminoglycosides; intrinsic resistance to ampicillin and first-generation cephalosporins. Surgical debridement if necrotic tissue present. Infectious disease consultation for breakthrough infections.
Prevention
Mandatory antibiotic prophylaxis: ciprofloxacin 500 mg PO BID + TMP-SMX DS BID, initiated 1+ hours before first leech and continuing 24h after last leech. Extended 10-14 days for immunocompromised. Avoid use of ampicillin or first-generation cephalosporins (intrinsic Aeromonas resistance).
Primary Literature
Whitaker et al. 2012 (Microsurgery, systematic review n=277); Mumcuoglu 2014 (IMAJ, prophylaxis guidelines); Herlin et al. 2017 (JPRAS, dual-agent protocol); Lineaweaver et al. 1992 (foundational transmission study); de Chalain 1996; FCM 2022 (43% environmental ciprofloxacin resistance)
Post-Detachment Bleeding (Therapeutic, Not Adverse)Universal (100% — by design)
Frequency
100% of patients (this is the therapeutic effect, not a complication)
Mechanism
Hirudin and other anticoagulant compounds in leech saliva inhibit thrombin, factor Xa, and platelet aggregation locally. Anticoagulant effect persists 4-24 hours after leech detachment, producing continued local bleeding. Total post-detachment volume: 50-150 mL per bite site.
Presentation
Continuous oozing from triradiate (Y-shaped) bite mark for 4-24 hours post-detachment. Bleeding is steady, not pulsatile. Volume can be substantial enough to require dressing changes every 2-4 hours during peak phase.
Management
Expected and therapeutic — should NOT be stopped artificially in most cases. Apply absorbent dressing; change every 4-8 hours. If bleeding exceeds expected pattern (>200 mL per site, or persisting >24 hours), assess for: (a) concomitant anticoagulation; (b) underlying coagulopathy not identified at screening; (c) inadvertent application to arterial vessel territory.
Prevention
Excessive bleeding prevention: (a) Screen for coagulopathy pre-treatment (CBC, coagulation panel); (b) Discontinue aspirin/NSAIDs 7-10 days/3-5 days respectively before elective treatment; (c) Verify bleeding cessation before patient discharge; (d) Educate patient about expected bleeding pattern to prevent confusion with complication.
Primary Literature
Standard hirudotherapy literature; Markwardt 1957 (hirudin pharmacology)
Excessive Bleeding / Transfusion-RequiringUncommon (outpatient); Common (microsurgical with prolonged courses)
Frequency
~50% of microsurgical patients receive transfusion support over prolonged leech therapy course (Whitaker 2012); <1% of outpatient single-session OA patients
Mechanism
Cumulative blood loss from multiple-leech multiple-session protocols exceeds physiologic compensation. Compounded by concomitant anticoagulation, aspirin/NSAIDs, or underlying bleeding diathesis.
Presentation
Progressive anemia (Hgb decline), tachycardia, lightheadedness, fatigue. In severe cases: orthostatic hypotension, syncope, decompensation requiring transfusion.
Management
Serial CBC monitoring during prolonged protocols. Transfusion criteria per institutional policy (typically Hgb <7 g/dL in stable adults, <8 g/dL with cardiopulmonary disease, <9 g/dL in active bleeding setting). Cross-matched blood availability for high-volume microsurgical applications. Adjust leech application frequency if cumulative loss exceeds patient tolerance.
Prevention
Pre-treatment hemoglobin assessment (≥10 g/dL recommended for elective non-microsurgical applications). Maintain Hgb >8 g/dL during ongoing therapy. Iron supplementation consideration for prolonged courses. Crossmatch blood for high-risk microsurgical patients.
Primary Literature
Whitaker 2012 (~50% transfusion rate in microsurgery cohort)
Local Histamine-Mediated Reaction (Pruritus, Erythema)Common (37-75%)
Frequency
37-75% of patients experience some degree of local histamine reaction (pruritus, erythema, mild edema). NOT a true allergy — does not preclude future treatment.
Mechanism
Leech salivary mixture contains histamine and histamine-releasing factors. Local mast cell degranulation produces classic histamine response. Not IgE-mediated (no sensitization to specific allergens required).
Presentation
Itching, redness, mild swelling around bite site within minutes to hours of leech attachment. Symptoms peak at 24-48 hours and resolve over 2-7 days. NOT progressive; NOT systemic; NOT associated with anaphylaxis risk.
Management
Symptomatic relief: oral antihistamine (cetirizine 10 mg, diphenhydramine 25-50 mg as needed); topical hydrocortisone 1% if marked erythema. Avoid scratching to prevent secondary bacterial infection. Reassure patient — this is expected response, not allergy.
Prevention
No specific prevention. Patient education before treatment to anticipate this normal reaction reduces anxiety.
Primary Literature
Standard hirudotherapy literature; Michalsen 2003 + Andereya 2008 RCT patient experience data
True IgE-Mediated AnaphylaxisRare to Very Rare (0.01-0.1%)
Frequency
Estimated <1 in 1000 cases; isolated case reports in literature; documented but uncommon
Mechanism
IgE-mediated hypersensitivity to specific leech salivary proteins (most likely hirudin, calin, or other polypeptide allergens). Requires prior sensitization (prior leech exposure or cross-reactive antigen). Mast cell degranulation produces systemic histamine release.
Presentation
Symptoms within 5-30 minutes of leech application: full-body urticaria, angioedema (face/lips/tongue), respiratory distress (wheeze, stridor), tachycardia, hypotension, gastrointestinal symptoms. May progress rapidly to airway compromise and shock.
Management
Emergency response: (1) Stop leech application immediately; (2) IM epinephrine 0.3-0.5 mg (adult) or 0.01 mg/kg (pediatric, max 0.3 mg); (3) Activate emergency response (call code/911); (4) IV access; (5) IV normal saline bolus 20 mL/kg; (6) IV diphenhydramine 25-50 mg; (7) IV methylprednisolone 125 mg; (8) Continuous monitoring; (9) ICU disposition. Anaphylaxis is an absolute contraindication to future leech therapy.
Prevention
Pre-treatment screening for prior leech exposure and reaction. Available emergency anaphylaxis medications at every leech application location. Initial dose may be administered in monitored setting for high-risk patients.
Primary Literature
Case reports in dermatology and emergency medicine literature; safety-protocols.json anaphylaxis section
Vasovagal Syncope During ApplicationUncommon (1-5%)
Frequency
1-5% of patients during procedure (similar to other venipuncture-equivalent procedures)
Mechanism
Visual stimulus of leech application, anxiety, dehydration, fasting state, or autonomic predisposition triggers parasympathetic activation, bradycardia, hypotension, and reduced cerebral perfusion.
Presentation
Lightheadedness, nausea, pallor, sweating, bradycardia (heart rate <60), hypotension (systolic <90), syncope. Onset typically within first 5 minutes of leech application or during sustained-feeding period.
Management
Supportive care: (a) Recumbent position with legs elevated; (b) IV fluids if available; (c) Continuous monitoring; (d) Atropine 0.5 mg IV if severe bradycardia (HR <40). Vasovagal episode typically resolves within minutes. Distinguish from true cardiovascular events.
Prevention
Pre-procedure preparation: (a) Adequate hydration; (b) Light meal 1-2 hours before; (c) Anxiolytic conversation; (d) Optional pre-procedure benzodiazepine for very anxious patients; (e) Recumbent positioning during first application for known fainters.
Primary Literature
Standard venipuncture vasovagal literature; safety-protocols.json
Permanent Triradiate ScarringUniversal (cosmetic)
Frequency
Triradiate (Y-shaped) scar 2-5 mm in every leech bite; some fading over 6-12 months but typically faintly visible long-term
Mechanism
Leech tripartite jaw creates characteristic Y-shaped wound. Wound healing produces small scar of similar geometry. Skin pigmentation changes (mild darkening or lightening) sometimes occur and are usually not permanent.
Presentation
Small Y-shaped scar 2-5 mm at each bite site. May persist as faint mark indefinitely. Cosmetic significance varies by location and individual healing patterns.
Management
No specific treatment needed for normal scarring. For cosmetic improvement: silicone sheets or gels, sun protection during healing phase to prevent hyperpigmentation. Surgical scar revision rarely needed.
Prevention
Informed consent: every patient must be informed of permanent triradiate scarring before treatment. For cosmetically sensitive areas (face, visible body areas), discuss explicitly and consider alternative treatment options.
Primary Literature
Standard wound healing literature
Hypertrophic Scarring / KeloidUncommon (1-5%, higher in patients with keloid tendency)
Frequency
Variable by patient and site; significantly higher in patients with documented keloid history, certain ethnic groups, or specific anatomic locations (presternum, deltoid).
Mechanism
Excessive collagen deposition during wound healing produces raised, hypertrophic scarring beyond the original wound boundaries (keloid) or staying within bounds (hypertrophic).
Presentation
Raised, firm, sometimes itchy or painful scarring developing 1-3 months post-bite. Keloids may continue to grow beyond original wound margin; hypertrophic scars stabilize within margin.
Management
Intralesional corticosteroid injections (triamcinolone), silicone gel/sheets, pressure therapy. For symptomatic keloids: dermatology consultation. Avoid scar revision surgery unless medically necessary (can trigger larger keloid).
Prevention
Pre-treatment screening for keloid history. For known keloid tendency: relative contraindication to elective hirudotherapy in cosmetically sensitive areas. Discuss alternatives.
Primary Literature
Dermatology scar-healing literature; not specifically hirudotherapy-quantified
Severe Disseminated Aeromonas Infection / SepsisRare (0.01-0.1% with prophylaxis)
Frequency
Rare but documented. Most reported in immunocompromised patients or those without proper prophylaxis. Mortality reported in isolated cases.
Mechanism
Aeromonas hydrophila bacteremia progressing to systemic infection. Particularly aggressive in patients with hepatic disease, immunosuppression, or impaired host defenses.
Presentation
Initial wound infection progressing to bacteremia, sepsis, septic shock. Symptoms: fever, hemodynamic instability, multi-organ dysfunction. Necrotizing soft tissue infection in severe cases.
Management
Sepsis bundle activation per institutional sepsis protocol: blood cultures + lactate; empiric broad-spectrum antibiotics (vancomycin + meropenem or piperacillin-tazobactam pending susceptibilities); aggressive fluid resuscitation; vasopressor support; ICU admission; surgical debridement of necrotic tissue; infectious disease and critical care consultation.
Prevention
Mandatory antibiotic prophylaxis. Avoidance in patients with severe hepatic disease (relative contraindication). Enhanced surveillance in immunocompromised. Surgeon awareness and rapid recognition.
Primary Literature
Aeromonas sepsis case reports; one documented lethal case (A. veronii); Aeromonas meningitis case report
Aeromonas MeningitisVery Rare (<0.01%)
Frequency
Isolated case reports; documented but exceedingly rare
Mechanism
Bacteremic seeding of cerebrospinal fluid; most commonly in immunocompromised patients or those with disrupted blood-brain barrier.
Presentation
Fever, severe headache, meningeal signs (neck stiffness, photophobia), altered mental status. Develops days to weeks after leech therapy in susceptible patients.
Management
Lumbar puncture (with appropriate safety considerations); empiric broad-spectrum antibiotics with CSF penetration (ceftriaxone 2 g IV q12h plus ampicillin if Listeria coverage needed, plus vancomycin if MRSA coverage); ICU admission; infectious disease and neurology consultation.
Prevention
Avoidance in patients with disrupted blood-brain barrier or known immune compromise. Mandatory antibiotic prophylaxis. Enhanced surveillance.
Primary Literature
Published case reports in infectious disease literature
Inadvertent Application to Arterial TerritoryVery Rare
Frequency
Should not occur with proper technique; isolated reports
Mechanism
Leech accidentally placed near or on artery instead of intended venous-congested tissue. Pulsatile arterial bleeding may result.
Presentation
Bright red, pulsatile bleeding inconsistent with normal post-detachment pattern. Volume may be substantial.
Management
Direct pressure, surgical exploration if bleeding cannot be controlled, transfusion as needed. Anatomic review for protocol adjustment.
Prevention
Anatomic review before each application. Identify and avoid arterial territories. Knowledge of patient-specific vascular anatomy especially in trauma/reconstruction patients.
Primary Literature
Isolated reports
Leech Migration (Wandering)Uncommon to Rare
Frequency
Variable; depends on application technique and supervision
Mechanism
Leech crawls from intended bite site to alternative location before establishing attachment. May enter natural orifices in extreme cases.
Presentation
Leech found at unexpected location; failed feeding at intended site; rare reports of nasal, oral, vaginal, or rectal entry.
Management
Locate and remove the leech. If embedded in orifice: examine carefully, often saline irrigation triggers release; medical instrumentation if needed. Apply at intended site with fresh leech.
Prevention
Use small medical apparatus (cup, tube) to restrict leech movement during initial attachment phase. Continuous supervision during early feeding. Avoid loose application near body openings.
Primary Literature
Case reports in emergency medicine literature
Difficult DetachmentUncommon
Frequency
Occasional difficulty with mature, fully-engorged leech detachment
Mechanism
Leech jaw retains grip even after feeding completion. Rare cases of broken-off jaw fragment.
Presentation
Leech not voluntarily detaching after expected feeding time. Forceful removal may break jaw, leaving fragment in wound.
Management
DO NOT pull forcefully. Apply salt, vinegar, or 70% ethanol to leech body — causes voluntary release. If jaw fragment retained: irrigation and removal under medical supervision.
Prevention
Allow voluntary detachment (typically 20-60 minutes). Avoid premature interruption. Train staff in proper detachment technique.
Primary Literature
Standard hirudotherapy practice
Patient Psychological Distress (Significant)Uncommon
Frequency
Variable; severe distress requiring procedural pause estimated <5%
Mechanism
Phobia of leeches (helminthophobia, bdellophobia), trauma history, or anxiety amplified by procedure visualization. May lead to acute panic, fight-or-flight response, or post-procedure psychological sequelae.
Presentation
Severe anxiety, hyperventilation, panic attack, refusal to continue procedure. Some patients report post-procedure psychological distress (intrusive thoughts, sleep disturbance).
Management
Stop procedure if patient consent withdrawn. Acute panic management: reassurance, slow breathing exercises, optional benzodiazepine. Post-procedure counseling referral for severe distress.
Prevention
Pre-procedure counseling. Visual desensitization (showing leech in container before application). Distraction techniques during application. Optional anxiolytic premedication for highly anxious patients.
Primary Literature
Procedural phobia literature; patient-experience surveys
Drug Interaction: Cipro + WarfarinCommon in patients on warfarin (drug-drug interaction)
Frequency
Predictable interaction; affects all patients on concurrent therapy
Mechanism
Ciprofloxacin inhibits CYP1A2 metabolism of (S)-warfarin and displaces warfarin from protein binding sites. INR elevation typical.
Presentation
Elevated INR within 5-10 days of starting ciprofloxacin. May reach supratherapeutic levels with bleeding risk.
Management
Increase INR monitoring frequency to every 2-3 days during co-administration. Empiric warfarin dose reduction 25-50% may be needed. Consider alternative antibiotic if patient cannot be monitored intensively.
Prevention
Pre-treatment INR documentation. Pharmacist verification of warfarin status. EMR alert. Patient education about bleeding signs.
Primary Literature
Drug-interaction literature (well-established); pharmacy clinical practice
Drug Interaction: TMP-SMX + ACE Inhibitor (Hyperkalemia)Uncommon
Frequency
Predictable interaction; elderly and chronic kidney disease patients at higher risk
Mechanism
TMP-SMX blocks epithelial sodium channels in distal tubule, mimicking potassium-sparing diuretic effect. Compounded with ACE inhibitor-induced reduced aldosterone signaling produces clinically significant hyperkalemia.
Presentation
Asymptomatic potassium elevation to symptomatic hyperkalemia (muscle weakness, arrhythmia). May cause cardiac complications in severe cases.
Management
Pre-treatment electrolyte monitoring. Avoid TMP-SMX in patients on ACE inhibitors/ARBs if alternative antibiotic available. If TMP-SMX necessary: enhanced monitoring (potassium every 3-5 days), kidney function assessment, patient education.
Prevention
Drug-interaction screening pre-prescription. Consider alternative antibiotic (e.g., ciprofloxacin monotherapy with careful Aeromonas surveillance) in high-risk patients.
Primary Literature
Drug-interaction literature; clinical pharmacy practice
Antibiotic-Associated Diarrhea (including C. difficile)Common (1-10%)
Frequency
Antibiotic-associated diarrhea: 5-25% with broad-spectrum antibiotics; C. difficile colitis: <5% with prophylaxis duration
Mechanism
Disruption of normal gut microbiome by prophylactic antibiotics enables overgrowth of C. difficile or other pathogens.
Presentation
Watery diarrhea, abdominal cramping, fever (more severe in CDI). Onset typically during or shortly after antibiotic course.
Management
Mild AAD: hydration support, probiotic consideration, symptomatic care. Suspected CDI: stop offending antibiotic if possible, test for C. difficile, treat per IDSA guidelines (vancomycin oral or fidaxomicin).
Prevention
Minimize prophylaxis duration to required minimum (typically 24h post-last leech). Avoid extended courses unless clinically necessary. Consider probiotics during prolonged antibiotic exposure.
Primary Literature
Antibiotic-associated diarrhea/CDI literature; IDSA guidelines
Ciprofloxacin Tendinopathy / Tendon RuptureUncommon to Rare (0.1-1%)
Frequency
Tendinopathy in approximately 1 per 1000 fluoroquinolone courses; rupture rarer; elevated risk in elderly, corticosteroid users, transplant recipients
Mechanism
Fluoroquinolone-induced collagen disruption in tendon matrix. Achilles tendon most commonly affected.
Presentation
Tendon pain (most commonly Achilles) within days to weeks of starting fluoroquinolone. May progress to acute rupture.
Management
Discontinue fluoroquinolone immediately if tendinopathy symptoms; substitute alternative antibiotic (TMP-SMX monotherapy or doxycycline). For acute rupture: orthopedic consultation, immobilization.
Prevention
Avoid fluoroquinolones in patients age >60 with steroid use, transplant recipients, or with prior tendinopathy. Use TMP-SMX monotherapy with enhanced Aeromonas surveillance in high-risk patients.
Primary Literature
FDA Black Box warning; fluoroquinolone safety literature
TMP-SMX Allergic Reaction (Including SJS/TEN)Uncommon to Rare
Frequency
Mild rash: 3-10%; severe reactions (SJS/TEN): <1 per 1000
Mechanism
Type IV hypersensitivity or rare severe cutaneous adverse reaction. Sulfonamide-related.
Presentation
Mild: maculopapular rash within 7-14 days. Severe: Stevens-Johnson syndrome, toxic epidermal necrolysis with mucosal involvement, fever, systemic symptoms.
Management
Mild rash: stop TMP-SMX, antihistamines. Severe reaction: emergency dermatology consultation, supportive care in burn-unit-equivalent setting, IVIG and/or cyclosporine per current SJS/TEN protocols.
Prevention
Screen for prior sulfonamide allergy. Patient education about rash recognition. Discontinue TMP-SMX at first sign of significant rash.
Primary Literature
Sulfonamide hypersensitivity literature; SJS/TEN management guidelines
Necrotizing Fasciitis (Severe Aeromonas)Very Rare (<0.01%)
Frequency
Isolated case reports; particularly aggressive form of Aeromonas infection
Mechanism
Aeromonas hydrophila rare hyper-virulent strains producing rapid soft tissue necrosis. Often in immunocompromised, diabetic, or hepatic-disease patients.
Presentation
Rapidly progressive cellulitis with grey-purple discoloration, severe pain disproportionate to physical findings, hemorrhagic bullae, systemic toxicity. Develops within hours to days of bite site infection.
Management
Surgical emergency: immediate aggressive surgical debridement, broad-spectrum IV antibiotics, ICU management, possible amputation. Mortality high without rapid intervention.
Prevention
Mandatory prophylaxis. Avoidance in highest-risk patients (decompensated cirrhosis, severe immunocompromise). Early recognition of cellulitis with rapid evaluation.
Primary Literature
Necrotizing soft tissue infection literature; Aeromonas-specific case reports
Allergic Cross-Reaction to Other AnticoagulantsRare
Frequency
Theoretically possible due to peptide cross-reactivity; isolated case reports
Mechanism
Patients previously sensitized to lepirudin or bivalirudin may have cross-reactive IgE to native hirudin in leech saliva.
Presentation
Anaphylaxis-like reaction during first leech application in patient with prior DTI exposure.
Management
Treat as anaphylaxis. Document permanent contraindication to all hirudin-class compounds including future leech therapy.
Prevention
Screen for prior exposure to lepirudin (Refludan), bivalirudin (Angiomax), or desirudin (Iprivask). Caution in HIT patients with prior DTI history.
Primary Literature
Hypersensitivity literature; HIT/DTI safety data
Inadvertent Patient Self-Removal of LeechUncommon
Frequency
Patient anxiety or movement may displace leech mid-feeding
Mechanism
Patient mechanical interaction with leech (touching, brushing, body movement) causes premature detachment.
Presentation
Leech detaches before complete feeding. Reduced therapeutic effect.
Management
Apply fresh leech at site if continuing therapy. Counsel patient.
Prevention
Patient counseling about avoiding contact during feeding. Comfortable positioning. Distraction (phone, reading).
Primary Literature
Standard clinical practice
Wound HematomaUncommon
Frequency
Variable; more common in patients on antiplatelet therapy
Mechanism
Subcutaneous bleeding accumulation at bite site rather than external oozing.
Presentation
Painful subcutaneous swelling at bite site within 24 hours. Discoloration (purple, blue).
Management
Conservative: ice, elevation, observation. Aspiration only if very large, painful, or causing functional impairment. Rule out infection.
Prevention
Antiplatelet/anticoagulant management before treatment. Pressure dressing not over-tight (allows external bleeding).
Primary Literature
Standard wound complication literature
Pseudomonas Wound ContaminationVery Rare
Frequency
Isolated case reports; not typical Aeromonas-spectrum infection
Mechanism
Environmental contamination (water source, dressing materials, hands) introduces Pseudomonas aeruginosa into bite wound.
Presentation
Green-tinged wound discharge, characteristic Pseudomonas odor, slow-healing wound.
Management
Wound culture; appropriate antibiotic per susceptibility (typically anti-pseudomonal coverage — cefepime, piperacillin-tazobactam, or carbapenem).
Prevention
Aseptic technique. Sterile dressing application. Patient hand hygiene education.
Primary Literature
Wound infection literature; uncommon non-Aeromonas pathogens
Hyperpigmentation at Bite SiteCommon (cosmetic)
Frequency
Variable; more common in darker skin types and sun-exposed areas
Mechanism
Post-inflammatory hyperpigmentation following healing of bite wound. Melanin overproduction at site.
Presentation
Darker pigmentation at bite site, more visible in lighter surrounding skin, may persist months to years.
Management
Topical hydroquinone or other depigmenting agents (if cosmetically concerning). Strict sun protection (SPF 50+) for 6-12 months post-healing.
Prevention
Sun protection during healing phase. Counsel darker-skin patients about likelihood.
Primary Literature
Dermatology post-inflammatory hyperpigmentation literature
Loss of FDA-Cleared Supplier (Supply Chain)Rare (institutional risk, not patient AE)
Frequency
Three FDA-cleared suppliers globally; supply chain disruptions possible
Mechanism
Supplier production issues, regulatory holds, shipping disruptions could leave institutions without leeches at critical moment.
Presentation
Inability to source leeches during patient need; therapy interrupted or unavailable.
Management
Maintain primary + backup supplier accounts. Emergency interfacility transfer if leeches unavailable locally. Communicate with patient about delay.
Prevention
Dual-supplier strategy. Adequate inventory management. Membership in microsurgery networks for emergency sharing.
Primary Literature
Healthcare supply chain literature
Patient Refusal Mid-TreatmentUncommon
Frequency
Variable; ethical/operational consideration
Mechanism
Patient withdraws consent during ongoing therapy due to discomfort, anxiety, or other concerns.
Presentation
Patient requests cessation of treatment before clinical endpoint reached.
Management
Respect patient autonomy. Discuss concerns. Document refusal. Continue conservative management. Re-engage if patient changes mind.
Prevention
Comprehensive pre-procedure consent process. Address concerns prospectively. Ongoing patient communication.
Primary Literature
Medical ethics literature on informed consent
Inadequate Therapeutic ResponseVariable by indication
Frequency
Microsurgical salvage: ~10-15% fail to salvage despite leech therapy (Whitaker 2012, salvage rate 78-88%). OA: ~20-30% of patients in published RCTs do not achieve clinical response.
Mechanism
Underlying disease severity exceeds therapy effect; technical factors; patient-specific factors (medication, comorbidities); supplier batch variation.
Presentation
Persistent venous congestion despite leech therapy in microsurgery; absent or minimal pain reduction in OA.
Management
Microsurgery: re-assess for surgical re-exploration vs. continued conservative management. OA: trial different protocol parameters; consider alternative therapies.
Prevention
Patient selection per evidence-based criteria. Realistic counseling about expected response rates. Multimodal therapy approach.
Primary Literature
Whitaker 2012 + Michalsen 2003 + Andereya 2008 RCT data
Mucocutaneous Bleeding (rare patients)Very Rare
Frequency
Isolated reports in patients with underlying bleeding diathesis
Mechanism
Generalized hemostatic effect of absorbed leech anticoagulants in vulnerable patients.
Presentation
Nasal bleeding (epistaxis), gum bleeding, or rare gastrointestinal/genitourinary bleeding at unexpected distance from bite site.
Management
Stop further leech application. Hemostatic measures per source. Coagulation panel. Hematology consultation if recurrent.
Prevention
Pre-treatment coagulation screening. Identification of bleeding history. Conservative use in elderly or undiagnosed coagulopathy.
Primary Literature
Case reports; not common with proper screening
Cosmetic DissatisfactionUncommon
Frequency
Variable; depends on application site, patient expectations, healing patterns
Mechanism
Patient dissatisfaction with scar appearance, pigmentation, or general aesthetic outcome.
Presentation
Post-procedure patient complaint about appearance of bite sites.
Management
Validate patient concerns. Cosmetic referral (silicone gels, laser scar revision considerations). Honest pre-procedure consent essential to manage expectations.
Prevention
Thorough informed consent including photographic examples of typical scarring. Site selection awareness for cosmetically sensitive areas.
Primary Literature
Patient satisfaction literature
FDA MAUDE Surveillance Trends
The FDA Manufacturer and User Facility Device Experience (MAUDE) database tracks adverse event reports for medical devices. For medicinal leeches (K040187, K132958, K140907), MAUDE surveillance includes:
| Category | Value | Interpretation |
|---|---|---|
| Total reports | Limited number of reports per year (typical for established device classes) | Underreporting is common in medical device surveillance; MAUDE data represents lower-bound estimates. |
| Most frequent report types | Aeromonas infections, allergic reactions, bleeding complications | Consistent with published clinical literature. |
| Trends | No emerging novel adverse event patterns identified | Established safety profile. |
| Annual review | ASH reviews MAUDE database annually | Findings inform updates to this Atlas. |
Report Adverse Events
Healthcare providers and patients can report suspected adverse events through multiple channels:
FDA MedWatch
Voluntary reporting at fda.gov/medwatch or 1-800-FDA-1088
Institutional Risk Management
Internal incident reporting per hospital policy
ASH Reporting
Reports to ASH inform Atlas updates and benchmark analyses
Manufacturer
Direct report to leech supplier per FDA Medical Device Reporting requirements
Safety Protocols
Detailed safety protocols including contraindications, prophylaxis, and complications management.
View →Implementation Playbook
10-phase institutional adoption guide with quality metrics and pitfalls.
View →PMID Audit Status
Confirms which PMIDs cited in each adverse-event entry have been verified against PubMed.
View →Trusted Sources
70+ authoritative external sources including FDA MAUDE and primary safety literature.
View →